Segall Bryant & Hamill LLC Makes New $715,000 Investment in Innoviva, Inc. (NASDAQ:INVA)

Segall Bryant & Hamill LLC acquired a new position in Innoviva, Inc. (NASDAQ:INVA) during the third quarter, HoldingsChannel reports. The institutional investor acquired 37,039 shares of the biotechnology company’s stock, valued at approximately $715,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. EdgeRock Capital LLC purchased a new stake in shares of Innoviva during the second quarter valued at approximately $31,000. Bessemer Group Inc. grew its holdings in shares of Innoviva by 333.5% during the first quarter. Bessemer Group Inc. now owns 2,211 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 1,701 shares during the last quarter. Innealta Capital LLC purchased a new stake in shares of Innoviva during the second quarter valued at approximately $33,000. US Bancorp DE grew its holdings in shares of Innoviva by 24.5% during the third quarter. US Bancorp DE now owns 2,875 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 566 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Innoviva by 53.7% during the second quarter. GAMMA Investing LLC now owns 3,476 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,214 shares during the last quarter. Hedge funds and other institutional investors own 99.12% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Innoviva in a report on Tuesday, July 30th. StockNews.com downgraded shares of Innoviva from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 6th.

Innoviva Stock Up 0.5 %

Shares of Innoviva stock opened at $19.15 on Monday. The company has a market cap of $1.20 billion, a price-to-earnings ratio of 27.75 and a beta of 0.57. The company’s 50 day moving average is $19.60 and its 200 day moving average is $18.12. Innoviva, Inc. has a twelve month low of $13.57 and a twelve month high of $21.28. The company has a quick ratio of 1.64, a current ratio of 1.79 and a debt-to-equity ratio of 0.38.

Innoviva (NASDAQ:INVA) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.27 by ($0.25). Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The business had revenue of $89.51 million during the quarter. Research analysts anticipate that Innoviva, Inc. will post 0.33 EPS for the current year.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.